Given the recent finding of therapeutic benefit of ADCs in HER2-low breast cancer in the metastatic setting, identifying potential tumor types that might derive benefit of such approaches in the early-stage setting is of clinical interest. Here, ERBB2 is linked to breast carcinoma.